Ironwood to buy VectivBio for $1.15 billion to boost digestive disorder drugs portfolio

Ironwood Pharmaceuticals Inc said on Monday it will acquire Switzerland-based drug developer VectivBio Holding AG for $1.15 billion to boost its portfolio of experimental digestive disorder drugs.

Ironwood will pay $17 per share for VectivBio, a premium of about 43% to VectivBio's last close.